Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women

Authors

Clayton English
Anne Muhleisen
Jose A. Rey, Nova Southeastern UniversityFollow

Publication Title

P T

Publication Date

4-1-2017

Abstract

Flibanserin (Addyi) for female sexual interest/arousal disorder in premenopausal women.

Volume

42

Issue

4

First Page

237

Last Page

241

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

NSUWorks Citation

English, Clayton; Muhleisen, Anne; and Rey, Jose A., "Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women" (2017). Faculty Articles. 119.
https://nsuworks.nova.edu/hpd_corx_facarticles/119